We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to Know
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) closed the most recent trading day at $1,164.89, moving +1.04% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.49%. Elsewhere, the Dow gained 0.71%, while the tech-heavy Nasdaq added 2.26%.
Shares of the drugmaker witnessed a loss of 8.16% over the previous month, trailing the performance of the Medical sector with its loss of 1.14%, and the S&P 500's gain of 0.1%.
Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to go public on October 29, 2026. In that report, analysts expect Eli Lilly to post earnings of $9.56 per share. This would mark year-over-year growth of 36.18%. In the meantime, our current consensus estimate forecasts the revenue to be $22.08 billion, indicating a 25.46% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $36.1 per share and a revenue of $88.83 billion, representing changes of +49.11% and +36.28%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.52% upward. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
In the context of valuation, Eli Lilly is at present trading with a Forward P/E ratio of 31.94. For comparison, its industry has an average Forward P/E of 15.87, which means Eli Lilly is trading at a premium to the group.
It is also worth noting that LLY currently has a PEG ratio of 1.44. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.97 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 107, positioning it in the top 44% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to Know
Eli Lilly (LLY - Free Report) closed the most recent trading day at $1,164.89, moving +1.04% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 1.49%. Elsewhere, the Dow gained 0.71%, while the tech-heavy Nasdaq added 2.26%.
Shares of the drugmaker witnessed a loss of 8.16% over the previous month, trailing the performance of the Medical sector with its loss of 1.14%, and the S&P 500's gain of 0.1%.
Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to go public on October 29, 2026. In that report, analysts expect Eli Lilly to post earnings of $9.56 per share. This would mark year-over-year growth of 36.18%. In the meantime, our current consensus estimate forecasts the revenue to be $22.08 billion, indicating a 25.46% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $36.1 per share and a revenue of $88.83 billion, representing changes of +49.11% and +36.28%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.52% upward. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
In the context of valuation, Eli Lilly is at present trading with a Forward P/E ratio of 31.94. For comparison, its industry has an average Forward P/E of 15.87, which means Eli Lilly is trading at a premium to the group.
It is also worth noting that LLY currently has a PEG ratio of 1.44. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.97 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 107, positioning it in the top 44% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.